However, whether BTLA expression in the NSCLC microenvironment contributes to resistance to PD-1/PD-L1 blockade therapy and whether combined blockade of BTLA could improve the efficacy of PD-1/PD-L1 inhibitors are unclear. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.